SG11202110524VA - Compounds and conjugates thereof - Google Patents
Compounds and conjugates thereofInfo
- Publication number
- SG11202110524VA SG11202110524VA SG11202110524VA SG11202110524VA SG11202110524VA SG 11202110524V A SG11202110524V A SG 11202110524VA SG 11202110524V A SG11202110524V A SG 11202110524VA SG 11202110524V A SG11202110524V A SG 11202110524VA SG 11202110524V A SG11202110524V A SG 11202110524VA
- Authority
- SG
- Singapore
- Prior art keywords
- conjugates
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Detail Structures Of Washing Machines And Dryers (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962826393P | 2019-03-29 | 2019-03-29 | |
US202062964177P | 2020-01-22 | 2020-01-22 | |
PCT/EP2020/057984 WO2020200880A1 (en) | 2019-03-29 | 2020-03-23 | Compounds and conjugates thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202110524VA true SG11202110524VA (en) | 2021-10-28 |
Family
ID=69960637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202110524VA SG11202110524VA (en) | 2019-03-29 | 2020-03-23 | Compounds and conjugates thereof |
Country Status (26)
Country | Link |
---|---|
US (3) | US20200306243A1 (lt) |
EP (2) | EP3946464B1 (lt) |
JP (2) | JP7210770B2 (lt) |
KR (2) | KR102498681B1 (lt) |
CN (2) | CN113631196B (lt) |
AU (1) | AU2020252034B2 (lt) |
BR (1) | BR112021018986A2 (lt) |
CA (1) | CA3133757A1 (lt) |
CL (1) | CL2021002498A1 (lt) |
CO (1) | CO2021014566A2 (lt) |
CR (1) | CR20210541A (lt) |
DK (1) | DK3946464T3 (lt) |
EC (1) | ECSP21078204A (lt) |
ES (1) | ES2930295T3 (lt) |
HR (1) | HRP20221280T1 (lt) |
HU (1) | HUE060364T2 (lt) |
IL (1) | IL286291A (lt) |
LT (1) | LT3946464T (lt) |
MX (1) | MX2021011812A (lt) |
PL (1) | PL3946464T3 (lt) |
PT (1) | PT3946464T (lt) |
RS (1) | RS63715B1 (lt) |
SG (1) | SG11202110524VA (lt) |
TW (1) | TWI826676B (lt) |
WO (1) | WO2020200880A1 (lt) |
ZA (1) | ZA202106612B (lt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11493668B2 (en) | 2018-09-26 | 2022-11-08 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
JP7210770B2 (ja) * | 2019-03-29 | 2023-01-23 | メドイミューン・リミテッド | 化合物及びその複合体 |
AU2020309570A1 (en) | 2019-07-10 | 2022-02-03 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
JP2022541747A (ja) | 2019-07-10 | 2022-09-27 | サイブレクサ 3,インコーポレイテッド | 治療薬としての微小管標的化剤のペプチドコンジュゲート |
TW202140076A (zh) * | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | 化合物及其軛合物 |
KR20220130749A (ko) * | 2020-01-22 | 2022-09-27 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
CN115703712A (zh) | 2021-08-17 | 2023-02-17 | 江苏迈威康新药研发有限公司 | 5,8-二氨基-3,4-二氢-2h-1-萘酮的合成方法以及其中采用的中间体化合物 |
WO2023109965A1 (zh) * | 2021-12-16 | 2023-06-22 | 迈威(上海)生物科技股份有限公司 | 一种喜树碱类化合物及其偶联物 |
TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
WO2023180485A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
WO2023180489A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
WO2023180490A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
WO2023180484A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing ptk7 |
CN115160403A (zh) * | 2022-07-05 | 2022-10-11 | 上海彩迩文生化科技有限公司 | 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4939255A (en) | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
JP2754022B2 (ja) * | 1988-11-18 | 1998-05-20 | 第一製薬株式会社 | カンプトテシン類縁体 |
JP3024013B2 (ja) * | 1990-08-14 | 2000-03-21 | 杏林製薬株式会社 | フルオロエチルカンプトテシン誘導体 |
US6407115B1 (en) | 1991-01-16 | 2002-06-18 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic compound |
JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
US5658920A (en) | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
JP3359955B2 (ja) * | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
DE69624796T2 (de) | 1995-02-22 | 2003-04-03 | Daiichi Seiyaku Co | Aminotetralon-derivate und verfahren zu deren herstellung |
US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
US5663177A (en) | 1995-05-31 | 1997-09-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
JPH1095802A (ja) * | 1995-12-28 | 1998-04-14 | Tanabe Seiyaku Co Ltd | カンプトテシン誘導体 |
IN189180B (lt) | 1997-07-09 | 2003-01-04 | Chong Kun Dang Corp | |
AR030207A1 (es) | 2000-04-07 | 2003-08-13 | Daiichi Seiyaku Co | Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma |
US6403604B1 (en) * | 2001-03-01 | 2002-06-11 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
EP1295864B1 (en) | 2001-05-08 | 2008-12-03 | Mitsui Chemicals Polyurethanes, Inc. | Process for preparation of 1,5-diaminonaphthalenes |
KR100895746B1 (ko) | 2001-11-30 | 2009-04-30 | 추가이 세이야쿠 가부시키가이샤 | 헥사사이클릭 화합물 |
US7595400B2 (en) | 2003-02-21 | 2009-09-29 | Chugai Seiyaku Kabushiki Kaisha | Process for the preparation of hexacyclic compounds |
NZ550665A (en) | 2004-04-09 | 2010-05-28 | Chugai Pharmaceutical Co Ltd | Novel water-soluble prodrugs of camptothecin derivatives |
ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
CA2927656C (en) | 2005-10-07 | 2019-09-24 | Exelixis, Inc. | Mek inhibitors and methods of their use |
EP1813614B1 (en) | 2006-01-25 | 2011-10-05 | Sanofi | Cytotoxic agents comprising new tomaymycin derivatives |
AR066476A1 (es) | 2007-05-08 | 2009-08-19 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos |
ES2450755T3 (es) | 2007-10-19 | 2014-03-25 | Genentech, Inc. | Anticuerpos anti-TENB2 modificados por ingeniería genética con cisteína, y conjugados de anticuerpo y fármaco |
KR20210100223A (ko) | 2008-04-30 | 2021-08-13 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
US8980909B2 (en) * | 2011-01-12 | 2015-03-17 | Crystal Biopharmaceutical Llc | HDAC inhibiting derivatives of camptothecin |
CN102850400A (zh) * | 2011-06-30 | 2013-01-02 | 周文强 | 喜树碱衍生物及其制备方法、药物组合物与用途 |
BR122021014365B1 (pt) * | 2012-10-11 | 2022-07-05 | Daiichi Sankyo Company, Limited | Conjugado de anticorpo-fármaco, fármacos e composição farmacêutica compreendendo os mesmos, e uso |
WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート |
US9962452B2 (en) * | 2013-02-04 | 2018-05-08 | Zhuhai Beihai Biotech Co., Ltd. | Soluble complexes of drug analogs and albumin |
EP3074010A4 (en) | 2013-11-27 | 2017-10-25 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
PL3088419T3 (pl) | 2013-12-25 | 2019-03-29 | Daiichi Sankyo Company, Limited | Koniugat lek-przeciwciało anty-trop2 |
CA2928794C (en) | 2014-01-31 | 2019-08-13 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-drug conjugate |
JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗cd98抗体−薬物コンジュゲート |
EP3130608B1 (en) | 2014-04-10 | 2019-09-04 | Daiichi Sankyo Co., Ltd. | (anti-her2 antibody)-drug conjugate |
KR102186027B1 (ko) | 2014-04-10 | 2020-12-03 | 다이이치 산쿄 유럽 게엠베하 | 항her3 항체-약물 콘주게이트 |
EP3733209A1 (en) | 2014-10-03 | 2020-11-04 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
US10844090B2 (en) | 2015-01-30 | 2020-11-24 | Sutro Biopharma, Inc. | Hemiasterlin derivatives for conjugation and therapy |
GB201506393D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
WO2017002776A1 (ja) | 2015-06-29 | 2017-01-05 | 第一三共株式会社 | 抗体-薬物コンジュゲートの選択的製造方法 |
MA43354A (fr) * | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
WO2018066626A1 (ja) | 2016-10-07 | 2018-04-12 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療 |
MA46789A (fr) | 2016-11-10 | 2019-09-18 | Medimmune Llc | Molécules de liaison spécifiques d'asct2 et leurs utilisations |
EP3552626A4 (en) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
WO2018135501A1 (ja) | 2017-01-17 | 2018-07-26 | 第一三共株式会社 | 抗gpr20抗体及び抗gpr20抗体-薬物コンジュゲート |
WO2018159582A1 (ja) | 2017-02-28 | 2018-09-07 | 学校法人近畿大学 | 抗her3抗体-薬物コンジュゲート投与によるegfr-tki抵抗性の非小細胞肺癌の治療方法 |
TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
WO2019034177A1 (zh) | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 具有两种不同药物的抗体药物偶联物 |
CN109106951A (zh) | 2017-08-18 | 2019-01-01 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
JP7210770B2 (ja) * | 2019-03-29 | 2023-01-23 | メドイミューン・リミテッド | 化合物及びその複合体 |
-
2020
- 2020-03-23 JP JP2021557758A patent/JP7210770B2/ja active Active
- 2020-03-23 CN CN202080025199.7A patent/CN113631196B/zh active Active
- 2020-03-23 CN CN202311084298.4A patent/CN117263948A/zh active Pending
- 2020-03-23 WO PCT/EP2020/057984 patent/WO2020200880A1/en active Application Filing
- 2020-03-23 US US16/826,405 patent/US20200306243A1/en not_active Abandoned
- 2020-03-23 EP EP20713873.6A patent/EP3946464B1/en active Active
- 2020-03-23 AU AU2020252034A patent/AU2020252034B2/en active Active
- 2020-03-23 PT PT207138736T patent/PT3946464T/pt unknown
- 2020-03-23 KR KR1020217035043A patent/KR102498681B1/ko active IP Right Grant
- 2020-03-23 DK DK20713873.6T patent/DK3946464T3/da active
- 2020-03-23 LT LTEPPCT/EP2020/057984T patent/LT3946464T/lt unknown
- 2020-03-23 HU HUE20713873A patent/HUE060364T2/hu unknown
- 2020-03-23 CA CA3133757A patent/CA3133757A1/en active Pending
- 2020-03-23 MX MX2021011812A patent/MX2021011812A/es unknown
- 2020-03-23 SG SG11202110524VA patent/SG11202110524VA/en unknown
- 2020-03-23 RS RS20221023A patent/RS63715B1/sr unknown
- 2020-03-23 EP EP22189090.8A patent/EP4176904A1/en active Pending
- 2020-03-23 BR BR112021018986A patent/BR112021018986A2/pt unknown
- 2020-03-23 US US17/599,374 patent/US20220211863A1/en active Pending
- 2020-03-23 HR HRP20221280TT patent/HRP20221280T1/hr unknown
- 2020-03-23 PL PL20713873.6T patent/PL3946464T3/pl unknown
- 2020-03-23 CR CR20210541A patent/CR20210541A/es unknown
- 2020-03-23 ES ES20713873T patent/ES2930295T3/es active Active
- 2020-03-23 KR KR1020237003605A patent/KR20230023814A/ko active IP Right Grant
- 2020-03-27 TW TW109110410A patent/TWI826676B/zh active
-
2021
- 2021-06-15 US US17/348,236 patent/US11446292B2/en active Active
- 2021-09-08 ZA ZA2021/06612A patent/ZA202106612B/en unknown
- 2021-09-12 IL IL286291A patent/IL286291A/en unknown
- 2021-09-27 CL CL2021002498A patent/CL2021002498A1/es unknown
- 2021-10-22 EC ECSENADI202178204A patent/ECSP21078204A/es unknown
- 2021-10-28 CO CONC2021/0014566A patent/CO2021014566A2/es unknown
-
2023
- 2023-01-11 JP JP2023002495A patent/JP2023065346A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286291A (en) | their compounds and conjugates | |
IL285178A (en) | compounds and their use | |
IL278877B1 (en) | Amino-pyrazinecarboxamide compounds, conjugates and their uses | |
IL285177A (en) | compounds and their use | |
SG11202101517PA (en) | Isoquinoline-steroid conjugates and uses thereof | |
IL286847A (en) | hsp90-binding couplers and formulations thereof | |
ZA202105752B (en) | Haloallylamine compounds and application thereof | |
IL286497A (en) | compounds and their use | |
IL277791A (en) | HSP90 targeting conjugates and their formulations | |
IL291499A (en) | Azaquinoline compounds and their uses | |
IL284764A (en) | compounds and their uses | |
IL285118A (en) | compounds and their uses | |
GB201820626D0 (en) | Conjugates | |
GB201820864D0 (en) | Antibody-drug conjugates | |
GB201903535D0 (en) | Compounds and conjugates | |
GB201903541D0 (en) | Compounds and conjugates | |
IL288681A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201906997D0 (en) | Conjugates | |
GB201900735D0 (en) | Conjugates | |
ZA202201239B (en) | Aminothiolester compounds and uses thereof | |
GB202000121D0 (en) | Compounds and conjugates | |
GB201811335D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201811332D0 (en) | Pyrroloobenzodiazepine-antibody conjugates | |
GB201908126D0 (en) | Pyrrolobenzodiazepine conjugates | |
GB201905117D0 (en) | Pyrrolobenzodiazepine conjugates |